Court-Ordered Access To Experimental PTC Drug Shows Risks Of Patient Outreach

A judge's decision to order PTC Therapeutics to provide an experimental drug for a teenage boy with Duchenne Muscular Dystrophy highlights the need for caution in communications with patients and their families, particularly in cases of life-threatening disease